BioSpace News Archive

Final Results for the Year Ended 31 December 2020 for Hemogenyx Pharmaceuticals plc

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system in women with BMI < 25 kg/m 2 and women with BMI 25-30 kg/m 2 will be presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting from April 30-May 2

Applauds Decisive Move and Commitment by FDA to Advance Rule Banning Menthol As First Step to Reduce Addiction, Improve Quitting, Reduce Youth Initiation and Reduced Disparities; Movement on Nicotine Cap by FDA Expected to be Forthcoming

Santhera Pharmaceuticals AG (SIX: SANN) announces that it has issued 2,312,000 treasury shares.

Immunicom, Inc., a clinical-stage biotechnology company pioneering “subtractive” advanced cancer therapies, presented promising preliminary data from trials investigating ImmunopheresisTM therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the publication of its 2021 Universal Registration Document, filed with the French Financial Market Authorities, Autorité des Marchés Financiers, on April 30, 2021.

Mayne Pharma announced results from two studies showing treatment with NEXTSTELLIS® demonstrated contraceptive efficacy and excellent cycle control across subgroups, including age, body mass index [1] and prior contraceptive use.

Leading health law firm McDermott Will & Emery is hosting its annual Physician Practice Management and ASC Symposium on May 6-7, 2021.

In order to humanize the battle against childhood brain tumors, this May during Brain Tumor Awareness Month, the Pediatric Brain Tumor Foundation invites the public to see the faces and names behind the disease.

Mechelen, Belgium;30 April 2021, 22.01 CET; regulated information –– Galapagos NV announced that its supervisory board created 2,736,250subscription rights under new subscription rightplans for the benefit of the personnelof the company and its subsidiaries.